Immunotherapy cocktail aims to turn untreatable stomach tumors into surgical targets
NCT ID NCT07638631
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) can shrink locally advanced stomach cancer that cannot be surgically removed. The goal is to make the tumors small enough for surgery. The study enrolls about 30 adults with PD-L1 positive, unresectable gastric cancer who have not had prior treatment. Researchers will measure how many patients become eligible for surgery and how well the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ipilimumab, sintilimab, and modified XELOX chemotherapy
What this could lead to
If successful, this combination could shrink inoperable stomach tumors enough to allow surgical removal, potentially improving long-term outcomes.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The combination of immunotherapy and chemotherapy can cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beta-blockers & Gastric Cancer: NCT07622693
- HIPEC + Immunotherapy for Gastric Cancer Trial NCT07621484
- PULSAR + Immunotherapy for Gastric Cancer (NCT07607119)
- Gastric Cancer Surgery Comparison After SOX + An NCT06597227
- AI Predicts Gastric Cancer Treatment Response (NCT07401199)
- Serplulimab Combo for Stomach Cancer Trial (NCT06576921)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••